Danaher delivered beats on the top and bottom lines for the third quarter on Thursday. But shares of the life sciences and medical diagnostics company remain under pressure after management was forced to lower expectations for one of its key businesses. Revenue for the period ended Sept. 30 declined 11.5% organically year over year to $6.87 billion, outpacing analyst estimates of $6.63 billion, according to Refinitiv. When excluding the 8.
Driving this forecast is an expectation for biotechnology sales to be down in the high-teens percentage range, life sciences sales to be about flat , and for diagnostics to be down in the mid-teens percentage point range. The adjusted operating profit margin is expected to be 29% — slightly better than the Street's 28%.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Danaher Tops Earnings and Revenue Estimates. The Stock Is Rising.Danaher posts third-quarter earnings of $2.02 a share on revenue of $6.87 billion.
Read more »
U.S. stocks open lower after 10-year Treasury yield tops 5% for first time since 2007Isabel Wang is a Markets Reporter for MarketWatch.
Read more »
Stocks Poised to Open HigherThis week features a smattering of earnings from Big Tech companies as well as GDP and inflation reports.
Read more »
Stocks extend slide, Chevron mega-deal, Apple slumps, 2-year auction on deck, Roivant drug saleStocks slide, Chevron mega-deal, Apple, 2-year auction, Roivant drug sale
Read more »
Too Much Value Concentrated in Seven US StocksTo say that the US markets are top-heavy is an understatement.
Read more »
Salesforce, Unity see their stocks fall after Piper Sandler abandons bullish stanceEmily Bary is a MarketWatch news editor based in New York.
Read more »